Bullish option flow detected in Pfizer (PFE) with 70,941 calls trading, 1.3x expected, and implied vol increasing over 1 point to 23.18%. Feb-25 25 calls and 2/28 weekly 25 puts are the most ...

Jefferies analyst Akash Tewari maintained a Buy rating on Pfizer (PFE – Research Report) today and set a price target of $33.00. The company’s shares opened today at $26.10. Leverage the power ...

PFIZER'S PAXLOVID FAILS AS 15-DAY TREATMENT FOR LONG COVID, STUDY FINDS Prosecutors said that certain prescribers who attended multiple speaker programs on the same topic received no educational ...

family members and colleagues who had no educational need to be there. Pfizer ended the Nurtec speaker programs after paying $11.5 billion to buy Biohaven in October 2022. "Patients deserve to ...

while other Biohaven speaker programs were attended by people with no educational need to be there, such as speakers’ spouses, family members or friends. Pfizer’s buyout of Biohaven officially ...

“That’s it. No proxy fight for Pfizer,” Faber said. Starboard announced that it built a $1 billion stake in the pharmaceutical giant in October. The activist investor was reportedly planning ...

Operator Good day, everyone and welcome to Pfizer's fourth-quarter 2024 earnings conference call. Today's call is being recorded. At this time, I would like to turn the call over to Francesca ...

Fitch considered EBITDA leverage (total debt/EBITDA) at or below 2.75x to be consistent with Pfizer's 'A' rating. Clearly, there is no expectation among rating agencies that Pfizer cannot pay off ...

But soon the Obama administration came down hard on such 'tax inversion' deals, changing laws such that the deal was no longer attractive to Pfizer. No signs of slowing down Despite some setbacks ...

In a world of wild talk and fake news, help us stand up for the facts.

Pfizer PFE-0.43%decrease; red down pointing triangle will pay $60 million to settle allegations that one of its subsidiaries incentivized healthcare providers to prescribe one of its drugs ...

US FDA approves AbbVie-Pfizer's treatment for intra-abdominal infections Robert F. Kennedy Jr., President Donald Trump's pick for health secretary, moved closer to securing the top health job on ...